Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

Merck & Co. logo
Merck & Co.MRK
——
Delcath Systems logo
Delcath SystemsDCTH
——

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s share based compensation arrangement by share based payment award options exercisable number?
Citius Oncology, Inc. (CTOR) reported share based compensation arrangement by share based payment award options exercisable number of $11.5M in Q1 2026.
How has Citius Oncology, Inc.'s share based compensation arrangement by share based payment award options exercisable number changed year-over-year?
Citius Oncology, Inc.'s share based compensation arrangement by share based payment award options exercisable number increased by 124.0% year-over-year, from $5.14M to $11.5M.